Drug discovery has always been costly and time-consuming. However, the main issue is not the expenses or the time it takes, but the fact that the classical process has been based on a trial-and-error approach on a massive level. Machine learning not only accelerates this process but also redefines the fundamental principles of the search for active compounds. The following five ways outline how this transformation is taking place.
Navigating Chemical Space Without Getting Lost
There are tens of billions of possible small molecule drugs. No lab could ever physically make, and consequently test, more than a tiny number of those. High-throughput screening improved things, but it still requires physical compounds to test.
Machine learning models can evaluate the predicted properties of virtual compounds at a scale that wet-lab methods never could. By training on existing molecular data, they learn to distinguish which regions of chemical space are worth exploring before a single gram of anything gets synthesized. A dramatically shorter list of candidates that are actually worth making is the result.
The role of quantum-informed simulation
When it comes to simulating molecular interactions at the quantum level, classical computing reaches its limitations. CPUs are sufficient to simulate basic molecular geometry, but they are not powerful enough to manage the electron-level activity that defines the binding of a drug to a protein target.
This is where the emerging intersection of AI and advanced physics plays a role in discovery science. Companies operating at this frontier, such as https://www.sandboxaq.com, are using AI in combination with quantum chemistry simulation of molecular behavior at a level of detail that ordinary computers cannot achieve.
Protein folding was already a hard problem. Simulating the dynamic chemistry that happens when a small molecule actually binds is harder. Quantum-informed AI models are the first realistic path toward solving it accurately.
De Novo Design: Specifying the Outcome First
Traditional medicinal chemistry often begins with a compound and observes its effects. In contrast, de novo molecular design starts with the biological result that researchers want to achieve. Then, it tries to work out which structures might achieve that result.
The difference here is that you’re not reliant on existing compound libraries. You’re not trying to find a compound that might already have been created. Instead, you’re simply creating candidates, potentially on a scope that’s impossible to cover experimentally. The computational filters can prevent the number of candidates from becoming unwieldy, turning a search problem into a design problem.
Predicting Toxicity Before Clinical Trials
One of the most costly phases in drug development is the gap between pre-clinical work and Phase I trials, sometimes called the “valley of death.” Compounds fail here for reasons that often could have been flagged earlier: off-target effects, metabolic instability, poor ADME profiles.
Deep learning models trained on historical safety data are now predicting these failure modes during the discovery phase. AI-led drug candidates have passed Phase I trials at rates of roughly 80-90%, compared to the industry average of 50-60%. That’s not a minor improvement, it represents a structural change in where resources get spent along the pipeline.
Toxicity prediction doesn’t replace clinical trials. It changes which compounds reach them.
Automating Lead Optimization
The first important step is to identify a promising compound. The subsequent step is to make sure that it is viable for development, meaning that it has the right potency, selectivity, solubility, and metabolic profile. This second step is known as lead optimization and it requires a huge amount of time.
Eroom’s Law has shown that over the years drug discovery has become slower and more expensive despite the fact that science has advanced. Most of this inefficiency is in the lead optimization phase since historically, that has been an iterative and manual process. We need to synthesize a molecule, test it, make changes in the chemical structure, and repeat. This process can take months.
ML can make this process shorter by predicting in advance which modifications are more likely to improve some properties without making others worse. Instead of running 200 synthesis cycles, you may only need to run 20 guided by a model. The model is trained with as many of the prior iterations as possible. Chemist will still be there. The number of blind alleys will just be smaller.
Where This is Heading
The overall impact of these five capabilities is greater than the sum of their parts. This is a transformational shift conducive to the prediction, optimization, filtration, adaptation, and continuous learning from failure of predictive models. AI can’t solve all the problems in drug discovery, but with machine learning-generated predictive models at least, it’s solving the foundational problem that is shedding a lot of waste from the system.
